3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, B-Cell
2
Recurrence
1
Pancreatic Neoplasms
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Bevacizumab
35
durvalumab
23
atezolizumab
22
Nivolumab
20
lenvatinib
19
tremelimumab
16
Specimen Handling
14
Magnetic Resonance Spectroscopy
12
sintilimab
11
pembrolizumab
9
Ipilimumab
9
tislelizumab
7
Sorafenib
7
cabozantinib
5
X-Rays
5
Immunoglobulin G
5
Disulfides
5
Cyclophosphamide
5
regorafenib
4
Radiotherapy
4
Radiosurgery
4
Radiation
4
Oxaliplatin
4
Immunotherapy
4
Ethiodized Oil
4
fludarabine
3
donafenib
3
Surgical Procedures, Operative
3
Folfox protocol
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
90 days
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled